Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
Rhea-AI Summary
Intellia Therapeutics (Nasdaq: NTLA) presented four posters at AAAAI 2026 on lonvoguran ziclumeran (lonvo-z; NTLA-2002) for hereditary angioedema (HAE). A pooled Phase 1/2 cohort (n=32) given a one-time 50 mg dose showed durable plasma kallikrein reductions and a mean monthly attack rate ≤0.2 through up to three years.
Key readouts: 96% mean reduction in HAE attacks versus baseline, 31/32 (97%) attack-free and LTP-free at data cutoff, and 86% of 28 patients with >6 months follow-up attack-free and LTP-free for >6 months. A patient survey (n=100) highlighted ongoing treatment burden.
Positive
- Mean monthly attack rate ≤0.2 through up to 3 years
- 96% mean reduction in HAE attacks from baseline
- 31 of 32 patients (97%) attack-free and LTP-free at data cutoff
- 86% of 28 patients with >6 months follow-up attack-free and LTP-free >6 months
Negative
- Small pooled sample size (n=32) limits generalizability
- Follow-up duration variable; some patients had as little as 2 months follow-up
- Survey (n=100) shows 34% report ≥1 attack per month, underscoring remaining unmet need
- Durability claims are ongoing and based on interim follow-up, not final long-term outcomes
Key Figures
Market Reality Check
Peers on Argus
NTLA’s setup shows strength while only one tracked peer, ZYME, appeared in momentum scans, moving -5.62% with no same-day news, suggesting stock-specific factors rather than a broad biotech move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Hold lifted MAGNITUDE | Positive | +12.1% | FDA removed clinical hold on MAGNITUDE Phase 3 ATTR-CM trial with safety changes. |
| Jan 27 | Hold lifted MAG-2 | Positive | +6.3% | FDA lifted clinical hold on MAGNITUDE-2 Phase 3 ATTRv-PN trial after protocol changes. |
| Nov 10 | Longer-term nex-z data | Positive | +2.2% | Reported 3-year Phase 1 nex-z data with deep TTR reduction and clinical stability. |
| Nov 08 | Pooled lonvo-z data | Positive | +2.2% | Presented pooled Phase 1/2 lonvo-z HAE data showing high attack-free, LTP-free rates. |
| Oct 27 | MAGNITUDE safety pause | Negative | -42.2% | Paused MAGNITUDE trials after Grade 4 liver enzymes and a serious safety event. |
Clinical trial headlines have generally produced directionally consistent moves: positive updates on nex-z and lonvo-z saw gains, while the MAGNITUDE safety pause coincided with a sharp decline.
Over the past months, Intellia’s key news flow has centered on clinical trial progress for nexiguran ziclumeran and lonvoguran ziclumeran. Events include a safety-driven pause of the MAGNITUDE programs on Oct 27, 2025, followed by positive longer-term Phase 1 data in ATTR-CM and pooled Phase 1/2 data in HAE in Nov 2025. In Jan–Mar 2026, sequential FDA lifts of clinical holds on MAGNITUDE-2 and MAGNITUDE allowed Phase 3 enrollment to resume with enhanced safety monitoring. Today’s HAE durability data extend this clinical narrative around one-time gene-editing treatments.
Historical Comparison
Across 5 recent clinical-trial headlines, NTLA’s average move was -3.89%, with large downside on safety issues offset by modest gains on positive data and hold removals.
Clinical news has tracked a path from an October 2025 MAGNITUDE safety pause through longer-term nex-z and lonvo-z data and into 2026 FDA hold removals. Today’s HAE durability data extend the sequence of updates on Intellia’s one-time CRISPR treatments.
Market Pulse Summary
This announcement highlights three-year durability and safety data for a one-time 50 mg dose of lonvo-z in HAE, with high attack-free and LTP-free rates and supporting mechanistic modeling. Survey data from 100 patients underscore substantial remaining treatment burden on chronic therapies. In the context of prior positive pooled lonvo-z data and recent FDA hold removals for nex-z trials, investors may watch for larger, later-stage HAE outcomes and any additional safety disclosures across Intellia’s gene-editing programs.
Key Terms
Phase 1/2 medical
long-term prophylaxis medical
hereditary angioedema medical
AI-generated analysis. Not financial advice.
Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients’ continued treatment burden and unmet needs
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced details about its presentation of four posters at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI) that took place this past weekend in Philadelphia, Pennsylvania. All posters are available on intelliatx.com on the Scientific Publications & Presentations page.
Poster Presentation Details:
- Title: Long-Term Durability and Safety of Lonvoguran Ziclumeran (Lonvo-z; NTLA-2002) 50 mg in Patients with Hereditary Angioedema
Session: Allergic Skin Diseases
Poster Number: 061
Presenter: Markus Magerl, M.D, Professor, Head of Clinical Trials, Charité - Universitätsmedizin Berlin Institute of Allergology- In this pooled Phase 1/2 analysis (n=32), a one-time 50 mg dose of lonvo-z led to deep, stable and durable reductions in plasma kallikrein across all patients with up to three years of follow-up.
- Across the 32 patients, the mean monthly attack rate was consistently ≤0.2, representing a mean reduction of
96% in HAE attacks from baseline through last follow-up. Of the 32 patients, 31 (97% ) were both attack-free and LTP-free as of the data cutoff, with the attack-free and LTP-free periods ranging from 2 months to 3 years with follow-up ongoing.
- Title: Evolving Treatment Goals to Achieve Freedom from Attacks and Long-Term Prophylaxis Following a One-Time Treatment with Lonvoguran Ziclumeran (Lonvo-z; NTLA-2002)
Session: Allergic Skin Diseases
Poster Number: 005
Presenter: Aleena Banerji, M.D., Professor at Harvard Medical School, Clinical Director of the Allergy and Clinical Immunology Unit at Massachusetts General Hospital- Recent research shows that achieving an attack-free status and simultaneously minimizing treatment burden are primary treatment goals for HAE experts and patients.
- Of the 28 patients with >6 months of follow-up after receiving a one-time 50 mg treatment of lonvo-z in a pooled Phase 1/2 analysis,
86% were attack-free and LTP-free for >6 months, a timeframe suggested by patients to be clinically meaningful.
- Title: Quantitative Systems Biology Modeling Estimates Extent of Excessive Kallikrein Generation in Hereditary Angioedema Patients
Session: Allergic Skin Diseases
Poster Number: 003
Presenter: Allen Kaplan, M.D., Professor, Department of Medicine, Medical University of South Carolina- This model suggested that HAE with significant C1-esterase inhibitor deficiency generates excess plasma kallikrein compared to healthy individuals, directly correlating with bradykinin increases.
- In this model, an
85% reduction in prekallikrein was shown to reduce peak free kallikrein and peak bradykin to near normal ranges. This level of reduction in prekallikrein is consistent with what has been observed clinically with a 50 mg dose of lonvo-z.
- Title: Chronic Medications Pose Challenges for People Living with Hereditary Angioedema
Session: Bridging Evidence for Real World Impact
Poster Number: 716
Presenter: Paula Busse, M.D., Professor, Department of Medicine, Division of Clinical Immunology, Mount Sinai Hospital- Among 100 surveyed U.S. patients with HAE,
89% of whom were on long-term prophylaxis therapies and11% of whom were on on-demand therapies only,34% reported having at least one attack per month and only20% reported being attack free in the prior year. - Most respondents indicated that eliminating lifetime chronic medication use and enhancing efficacy are the most important ways to improve their current therapy.
- Among 100 surveyed U.S. patients with HAE,
About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy that is currently being investigated in HAELO, a Phase 3 clinical trial in HAE, and is designed to prevent HAE attacks by inactivating the kallikrein B1 (KLKB1) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
FAQ
What were the three-year durability results for lonvo-z (NTLA) presented at AAAAI 2026?
How many patients were attack-free after a one-time 50 mg lonvo-z dose in the NTLA Phase 1/2 pooled analysis?
What percentage of patients remained attack-free for >6 months after lonvo-z (NTLA) treatment?
What safety or biomarker effects did the lonvo-z 50 mg dose show in the NTLA presentation?
What did the AAAAI 2026 patient survey reveal about HAE treatment burden relevant to NTLA (lonvo-z)?
What are the limitations of the lonvo-z results presented by Intellia (NTLA) at AAAAI 2026?
